Chimericantigen receptor for adoptiveimmunotherapy of cancer: latest research andfutureprospect
Chimeric antigen receptors (CARs) arerecombinant receptors that combine the specificity of an antigen-specificantibody with the T-cell’s activating functions. Initial clinical trials ofgenetically engineered CAR T cells have significantly raised the profile of Tcell therapy, and great efforts have been made to improve this approach. Inthis review, we provide a structural overview of the development of CARtechnology and highlight areas that requirefurther refinement. We also discusscritical issues related to CAR therapy, including the optimization of CAR Tcells, the route of administration, CAR toxicity and the blocking of inhibitorymolecules.